Condition: Non-alcoholic Fatty Liver Disease · Sponsor: GlaxoSmithKline
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Chandler, Arizona, United States | Recruiting |
| GSK Investigational Site | Tucson, Arizona, United States | Recruiting |
| GSK Investigational Site | Little Rock, Arkansas, United States | Recruiting |
| GSK Investigational Site | Arcadia, California, United States | Recruiting |
| GSK Investigational Site | Covina, California, United States | Recruiting |
| GSK Investigational Site | Folsom, California, United States | Recruiting |
| GSK Investigational Site | Los Angeles, California, United States | Recruiting |
| GSK Investigational Site | Montclair, California, United States | Recruiting |
| GSK Investigational Site | Riverdale, California, United States | Recruiting |
| GSK Investigational Site | San Diego, California, United States | Recruiting |
| GSK Investigational Site | Santa Maria, California, United States | Recruiting |
| GSK Investigational Site | Van Nuys, California, United States | Recruiting |
+ 79 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07221227